Mutasynthesis of Physostigmines in Myxococcus xanthus
The alkaloid physostigmine is an approved anticholinergic drug and an important lead structure for the development of novel therapeutics. Using a complementary approach that merged chemical synthesis with pathway refactoring, we produced a series of physostigmine analogues with altered specificity and toxicity profiles in the heterologous host Myxococcus xanthus. The compounds that were generated by applying a simple feeding strategy include the promising drug candidate phenserine, which was previously accessible only by total synthesis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Organic letters - 23(2021), 16 vom: 20. Aug., Seite 6563-6567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winand, Lea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9U1VM840SP |
|---|
| Anmerkungen: |
Date Completed 19.11.2021 Date Revised 19.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.orglett.1c02374 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328998664 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328998664 | ||
| 003 | DE-627 | ||
| 005 | 20231225204141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.orglett.1c02374 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM328998664 | ||
| 035 | |a (NLM)34355569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winand, Lea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mutasynthesis of Physostigmines in Myxococcus xanthus |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.11.2021 | ||
| 500 | |a Date Revised 19.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The alkaloid physostigmine is an approved anticholinergic drug and an important lead structure for the development of novel therapeutics. Using a complementary approach that merged chemical synthesis with pathway refactoring, we produced a series of physostigmine analogues with altered specificity and toxicity profiles in the heterologous host Myxococcus xanthus. The compounds that were generated by applying a simple feeding strategy include the promising drug candidate phenserine, which was previously accessible only by total synthesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Physostigmine |2 NLM | |
| 650 | 7 | |a 9U1VM840SP |2 NLM | |
| 650 | 7 | |a phenserine |2 NLM | |
| 650 | 7 | |a SUE285UG3S |2 NLM | |
| 700 | 1 | |a Schneider, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Kruth, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Greven, Nico-Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Hiller, Wolf |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Pietruszka, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Nett, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Organic letters |d 1999 |g 23(2021), 16 vom: 20. Aug., Seite 6563-6567 |w (DE-627)NLM106817639 |x 1523-7052 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:16 |g day:20 |g month:08 |g pages:6563-6567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.orglett.1c02374 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 16 |b 20 |c 08 |h 6563-6567 | ||